Fabbio Patrick 4

What Happened

• Patrick Fabbio, Chief Financial Officer of Protara Therapeutics (TARA), was issued two restricted stock unit (RSU) awards on January 16, 2026 totaling 203,000 RSUs: 28,000 RSUs (reported as direct shares, $0.00 per share) and 175,000 RSUs reported as a derivative grant (also $0.00 per share). RSUs are contingent rights to receive common stock if and when they vest. This is a compensation award, not a purchase or sale.

Key Details

• Transaction date: January 16, 2026; Form filed January 21, 2026.
• Consideration: $0.00 per share (awarded, not purchased).
• Grant totals: 28,000 RSUs + 175,000 RSUs = 203,000 RSUs.
• Vesting (per footnotes):
  • One grant: vests in equal one-third installments on the first, second and third anniversaries of Jan 16, 2026.
  • The other grant: 25% vests on the one‑year anniversary (Jan 16, 2027) and the remaining 75% vests monthly thereafter (structured as 1/48th of the total per month over the next three years).
• Shares owned after transaction: not specified in this Form 4.
• No 10b5-1 plan, tax‑withholding sale, or late‑filing indication noted in the filing.

Context

• RSU grants are standard executive compensation and do not indicate an immediate purchase/sale signal; they convert to actual shares only as they vest and subject to continued service.
• The 175,000 RSUs are reported as a derivative security (contingent right to future shares); simply put, Fabbio will receive shares later if he remains employed and vesting conditions are met.